References
- 1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4nd ed.), text revision (DSM-IV-TR). Washington DC: American Psychiatric Association, 2000.
- 2. Murray CJL, Lopez AD. The global burden of disease. Cambridge: Harvard University Press, 1996.
- 3. Kendler KS, Gallagher TJ, Abelson JM, Kessler RC. Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample: The National Comorbidity Survey. Arch Gen Psychiatry 1996; 53: 1022-1031.
- 4. Goldner EM, Hsu L, Waraich P, Somers JM. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can J Psychiatry 2002; 47: 833-843.
- 5. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161: 1334-1349.
- 6. Picchioni MM, Murray RM. Schizophrenia. BMJ 2007; 335: 91-95.
- 7. Dixon LB, Lehman AF, Levine J. Conventional antipsychotic medications for schizophrenia. Schizophr Bull 1995; 21: 567-577.
- 8. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41.
- 9. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of firstepisode schizophrenia. Am J Psychiatry 2000; 157: 514-520.
- 10. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W. Schizophrenia Patient Outcomes Research Team (PORT): the 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010; 36: 71-93.
- 11. Inštitut za varovanje zdravja Republike Slovenije. Ambulantno predpisovanje zdravil v Sloveniji po ATC Klasifikaciji v letu 2009. Pridobljeno 28.1.2012 s spletne strani: http://www.ivz.si.
- 12. IMS health. Pridobljeno 30.1.2012 s spletne strani: http://www.IMShealth.com.
- 13. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 2004; 21: 419-429.
- 14. Canuso CM, Dirks B, Carothers J, Kosik-Gonzalez C, Bossie CA, Zhu Y, Damaraju CV, Kalali AH, Mahmoud R. Randomized, double-blind, placebo-controlled study of paliperidoneextended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry 2009; 166: 691-701.
- 15. Canuso CM, Bossie CA, Turkoz I, Alphs L. Paliperidone extendedrelease for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms. Schizophr Res 2009; 113: 56-64.
- 16. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007; 90:147-161.
- 17. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito GG, Marder SR. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60: 681-690.
- 18. Kahn RS, Schulz SC, Palazov VD, Reyes EB, Brecher M, Svensson O, Andersson HM, Meulien D. Efficacy and tolerability of once-daily extended release quetiapinefumarate in acute schizophrenia: a randomized, double-blind, placebocontrolled study. J Clin Psychiatry 2007; 68: 832-842.
- 19. Arvanitis LA, Miller BG. Multiple fixed doses of „Seroquel“ (quetiapine) in patients with acute exacerbation of schizophrenia:a comparison with haloperidol and placebo. Biol Psychiatry 1997; 42: 233-246.
- 20. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M. Treatment of schizophrenia with paliperidoneextended-release tablets: a 6-week placebocontrolled trial. Schizophr Res 2007; 90: 147-161.
- 21. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, HsiaoJK. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigators: effectiveness of antipsychotic drugs in patientswith chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223.
- 22. Dossenbach M, Arango-Davila C, Silva Ibarra H, Landa E, Aguilar J,Caro O, Leadbetter J, Assuncao S. Response and relapse inpatients with schizophrenia treated with olanzapine, risperidone,quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (ICSOHO) study. J Clin Psychiatry 2005; 66: 1021-1030.
- 23. Mullins CD, Obeidat NA, Cuffel BJ, Naradzay J, Loebel AD. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. Schizophr Res 2008; 98: 8-15.
- 24. Lieberman JA, Stroup TS, McEvoy JP et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1023.
- 25. IMS health. Pridobljeno 30.1.2012 s spletne strani: http://www. IMShealth.com.
- 26. Zavod za zdravstveno zavarovanje Slovenije. Cene storitev v zdravstvu od 1.1. 2012 dalje. Pridobljeno 25.1.2012 s spletne strani: http://www.zzzs.si/zzzs/pao/izvajalci.nsf/o/0C38E1F23D 89C18FC125796F00173041.
- 27. Zakonodaja Republike Slovenije. Zakon o duševnem zdravju Republike Slovenije. Pridobljeno 20.1.2012 s spletne strani: http:// zakonodaja.gov.si/rpsi/r07/predpis_ZAKO2157.html.
- 28. Zavod za zdravstveno zavarovanje Republike Slovenije. Recept glasilo, zadnja verzija. Pridobljeno 20. 1. 2012 s spletne strani: http://www.zzzs.si/ZZZS/info/egradiva.nsf/0/2e6416e75fe33f0 5c125796c00492304/$FILE/Bilten%20Recept_%C5%A1t%20 1_20.12.2011.pdf
- 29. Geitona M, Kousoulakou H, Ollandezos M, Athanasakis K, Papanicolaou S, Kyriopoulos I. Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Annals of General Psychiatry 2008; 7: 16.
- 30. Hausmann A, Fleischhacker WW. Differential diagnosis of depressed mood in patients with schizophrenia: a diagnostic algorithm based on a review. Acta Psychiatr Scand 2002; 106: 83-96.
- 31. Premuš A, Mrhar A. Interakcije med zdravili pri bolnikih na kirurškem oddelku Splošne bolnišnice Murska Sobota. Zdrav Var 2010; 49: 189-201.
- 32. Lewis SW, Barnes TR, Davies L, Murray RM, Dunn G, Hayhurst KP. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006; 32: 715-723.
- 33. Obradović M, Mrhar A, Kos M. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia. Int J Clin Pract 2007; 6: 1979-1988.
- 34. Young W. The therapeutic window for methylprednisolone treatment of acute spinal cord injury: implications for cell injury mechanisms. Res Publ Assoc Res Nerv Ment Dis 1993; 71: 191-206.
- 35. Vera-Llonch M, Delea TE, Richardson E, Rupnow M, Grogg A, Oster G. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model. Value Health 2004; 7: 569-584.
- 36. Boscoe A, Paramore C, Verbalis JG. Cost of illness of hyponatremia in the United States. Cost Eff Resour Alloc 2006; 4: 10.